Tags

Type your tag names separated by a space and hit enter

Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man.
Thorax 1987; 42(12):946-52T

Abstract

The effect of flurbiprofen, a potent cyclo-oxygenase inhibitor, on histamine and methacholine reactivity was assessed in seven atopic subjects with asthma. Flurbiprofen 150 mg daily for three days displaced the histamine-FEV1 concentration-response curve to the right by 1.5 doubling doses, whereas no effect was observed on the response to methacholine. Subsequently the effects of flurbiprofen and terfenadine, a specific H1 histamine receptor antagonist, on allergen induced bronchoconstriction were studied in seven atopic but non-asthmatic subjects. The subjects inhaled the concentration of grass pollen allergen that had previously been shown to produce a 20% fall in FEV1 on separate occasions after prior treatment with placebo, flurbiprofen 150 mg daily for three days, terfenadine 180 mg three hours before challenge, and the combination of flurbiprofen and terfenadine. After placebo, allergen challenge caused a mean (SEM) maximum fall in FEV1 of 37.6% (2.6%) after 20 (3.7) minutes, followed by a gradual recovery to within 15% of baseline at 60 minutes. Terfenadine reduced the maximum allergen provoked fall in FEV1 to 21.5% (2.2%) and reduced the area under the time-response curve (AUC) by 50% (6%). Flurbiprofen alone reduced the mean maximum fall in FEV1 to 29.6% (3.2%) and reduced the AUC by 26%. The effect of the combination of flurbiprofen and terfenadine did not differ significantly from that of terfenadine alone. We conclude that histamine and prostaglandins contribute to immediate allergen induced bronchoconstriction and that a complex interaction occurs between the two classes of mediators.

Authors+Show Affiliations

Medicine 1, Southhampton General Hospital.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

2894081

Citation

Curzen, N, et al. "Effects of a Cyclo-oxygenase Inhibitor, Flurbiprofen, and an H1 Histamine Receptor Antagonist, Terfenadine, Alone and in Combination On Allergen Induced Immediate Bronchoconstriction in Man." Thorax, vol. 42, no. 12, 1987, pp. 946-52.
Curzen N, Rafferty P, Holgate ST. Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax. 1987;42(12):946-52.
Curzen, N., Rafferty, P., & Holgate, S. T. (1987). Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax, 42(12), pp. 946-52.
Curzen N, Rafferty P, Holgate ST. Effects of a Cyclo-oxygenase Inhibitor, Flurbiprofen, and an H1 Histamine Receptor Antagonist, Terfenadine, Alone and in Combination On Allergen Induced Immediate Bronchoconstriction in Man. Thorax. 1987;42(12):946-52. PubMed PMID: 2894081.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. AU - Curzen,N, AU - Rafferty,P, AU - Holgate,S T, PY - 1987/12/1/pubmed PY - 1987/12/1/medline PY - 1987/12/1/entrez SP - 946 EP - 52 JF - Thorax JO - Thorax VL - 42 IS - 12 N2 - The effect of flurbiprofen, a potent cyclo-oxygenase inhibitor, on histamine and methacholine reactivity was assessed in seven atopic subjects with asthma. Flurbiprofen 150 mg daily for three days displaced the histamine-FEV1 concentration-response curve to the right by 1.5 doubling doses, whereas no effect was observed on the response to methacholine. Subsequently the effects of flurbiprofen and terfenadine, a specific H1 histamine receptor antagonist, on allergen induced bronchoconstriction were studied in seven atopic but non-asthmatic subjects. The subjects inhaled the concentration of grass pollen allergen that had previously been shown to produce a 20% fall in FEV1 on separate occasions after prior treatment with placebo, flurbiprofen 150 mg daily for three days, terfenadine 180 mg three hours before challenge, and the combination of flurbiprofen and terfenadine. After placebo, allergen challenge caused a mean (SEM) maximum fall in FEV1 of 37.6% (2.6%) after 20 (3.7) minutes, followed by a gradual recovery to within 15% of baseline at 60 minutes. Terfenadine reduced the maximum allergen provoked fall in FEV1 to 21.5% (2.2%) and reduced the area under the time-response curve (AUC) by 50% (6%). Flurbiprofen alone reduced the mean maximum fall in FEV1 to 29.6% (3.2%) and reduced the AUC by 26%. The effect of the combination of flurbiprofen and terfenadine did not differ significantly from that of terfenadine alone. We conclude that histamine and prostaglandins contribute to immediate allergen induced bronchoconstriction and that a complex interaction occurs between the two classes of mediators. SN - 0040-6376 UR - https://www.unboundmedicine.com/medline/citation/2894081/Effects_of_a_cyclo_oxygenase_inhibitor_flurbiprofen_and_an_H1_histamine_receptor_antagonist_terfenadine_alone_and_in_combination_on_allergen_induced_immediate_bronchoconstriction_in_man_ L2 - http://thorax.bmj.com/cgi/pmidlookup?view=long&pmid=2894081 DB - PRIME DP - Unbound Medicine ER -